ABL Bio, Inc.
ABL Bio, Inc. has 1 licensing announcement in this dataset, dated 2025-04-07.
- Country / operating region
- South Korea
- Ticker
- 298380.KQ
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- www.ablbio.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| Grabody-B | 查無 | 查無 | 查無 | 2025-04-07 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| Grabody-B | 查無 | — | 查無 | 查無 | 查無 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2025-04-07 | GSK | Grabody-B | 查無 | 查無 | 查無 | 查無 | Potential total ≤ GBP 2140m Combined upfront + near-term GBP 77.1m Initial payments combine upfront and near-term milestones; components are not split in this selected source. |
| Counterparty | Territory | Royalties |
|---|---|---|
| GSK | Worldwide | 查無 |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無